hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06326788, orgStudyIdInfo id: 3912 Mehnoor Butt, briefTitle: Effects of Moderate Intensity Soleus Push-ups vs Sustained Soleus Push-ups on Lipid Profile Among Young Population, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-07-28, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: To determine the effects of Short duration moderate intensity soleus push- ups VS Sustained Soleus Push-ups on lipid profile among Young Population., conditionsModule conditions: Health Behavior, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 33, type: ESTIMATED, armsInterventionsModule interventions name: Short Duration Moderate Intensity Soleus Push-ups, interventions name: SUSTAINED SOLEUS PUSH-UPS, outcomesModule primaryOutcomes measure: Change in Lipid Profile, otherOutcomes measure: Adherence to Exercise Protocol, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 26 Years, stdAges: ADULT, contactsLocationsModule locations facility: Riphah Rehabilitation Center, status: RECRUITING, city: Islamabad, zip: 46600, country: Pakistan, contacts name: Mehnoor Butt, MSPT, role: CONTACT, phone: 335 5400831, email: mehnoorarshad1109@gmail.com, contacts name: Waqar Ahmed Awan, PHD, role: CONTACT, phone: 333 5348846, email: waqar.ahmed@riphah.edu.pk, geoPoint lat: 33.72148, lon: 73.04329, hasResults: False
protocolSection identificationModule nctId: NCT06326775, orgStudyIdInfo id: KY20240311-KS-02, briefTitle: Research on Precision Pharmaceutical Care for Heart Transplant Recipients, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Nanjing First Hospital, Nanjing Medical University, class: OTHER, collaborators name: Wuhan Union Hospital, China, collaborators name: Changhai Hospital, collaborators name: Shanghai Zhongshan Hospital, descriptionModule briefSummary: Establishing personalized dose prediction and related adverse drug reaction prediction models for immunosuppressive drugs after heart transplantation using multiple methods to construct a precise pharmaceutical service system for heart transplant patients has important research value and clinical significance in improving the safety and effectiveness of medication for patients., conditionsModule conditions: Heart Transplant Patients, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, outcomesModule primaryOutcomes measure: Steady state whole blood trough concentration of tacrolimus, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pharmacy Department of Nanjing First Hospital, city: Nanjing, state: Jiangsu, zip: 210006, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06326762, orgStudyIdInfo id: younes, briefTitle: Gap CO2 in Septic Patient to Predict Cardiomyopathy Septic, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-10-30, completionDateStruct date: 2023-10-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Mohammed VI University Hospital, class: OTHER, descriptionModule briefSummary: the investigators included 98 patients admitted for sepsis and septic shock (68.4% men, 31.6% women) with an average age of 60.42 years ± 15.13, ranging from 21 to 96 years. The average length of hospital stay was 7.53 days. The most noted medical histories were diabetes (38.8%), hypertension (28.6%), and renal insufficiency (17.1%). Regarding laboratory findings: the mean white blood cell count was 15,985.16 cells/mm³, the mean C-reactive protein (CRP) level was 227.69 mg/L, and the mean procalcitonin level was 50.43 µg/L. In terms of blood gas analysis: the mean lactate level was 3.67 mmol/L, and the mean PCO2 gap (DELTAPCO2) was 4.85. All our patients were continuously monitored by pulse wave analysis: the mean cardiac output was 5.69 L/min, and the mean cardiac index was 4.14 L/s/m² All our patients underwent an echocardiogram, which is a routine examination in our department and is performed at the patient's bedside. The average left ventricular ejection fraction (LVEF) was 51.73%, and the average subaortic peak velocity (ITV) was 14.66 cm.Subsequently. the investigators examined the clinical and paraclinical profile of patients with septic cardiomyopathy. the investigators identified 19 patients with this condition, while 79 patients did not exhibit cardiac involvement. The percentage was significantly higher in the population with cardiac involvement, accounting for 28.3%. Among the patients with cardiac involvement, 76.5% had a PCO2 gap (DELTAPCO2) ≥ 6 mmHg, a significantly reduced cardiac output with an average of 3.3 L/min, and a predominantly low cardiac index, with 64.3% having an index \< 2.2 L/min/m². The mortality rate was significantly increased at 73.7%., conditionsModule conditions: Gap co2, conditions: Cardiac Output, Low, conditions: Cardiac Defect, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 98, type: ACTUAL, armsInterventionsModule interventions name: comparaison, outcomesModule primaryOutcomes measure: gapCO2, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: younes Oujidi, city: Berkane, zip: 9999, country: Morocco, geoPoint lat: 34.92, lon: -2.32, hasResults: False
protocolSection identificationModule nctId: NCT06326749, orgStudyIdInfo id: 2024/19, briefTitle: Effectiveness of Modified Graded Motor Imagery Training in Stroke Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-11-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Inonu University, class: OTHER, descriptionModule briefSummary: In the study, movement observation training, Modified Graded Motor Imaging Training, which includes upper extremity functional exercises, and Graded Motor Imaging Training, where the standard protocol is applied, will be used in stroke patients to improve their upper extremity motor functions and daily lives. It is aimed to present it on an evidence-based basis by investigating its effects on Daily Living Activity, quality of life, upper extremity-specific right/left lateralization performance, mental stopwatch performance and motor imagery skills., conditionsModule conditions: Graded Motor Imagery, conditions: Stroke, conditions: Action Observation Training, conditions: Motor Imagery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 21, type: ESTIMATED, armsInterventionsModule interventions name: Modified Graded Motor Imagery and Conventional Treatment Group, interventions name: Graded Motor Imagery and Conventional Treatment Group, interventions name: Conventional Treatment Group, outcomesModule primaryOutcomes measure: Fugl-Meyer Upper Extremity Motor Rating Scale, primaryOutcomes measure: Wolf Motor Function Test (WMFT), primaryOutcomes measure: Modified Barthel Index, primaryOutcomes measure: Stroke-Specific Quality of Life Scale, secondaryOutcomes measure: Lateralization Assessment, secondaryOutcomes measure: Mental Chronometry Time, secondaryOutcomes measure: Kinesthetic and Visual Imagery Questionnaire (KGIA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Inonu University, city: Malatya, zip: 44280, country: Turkey, contacts name: Havva ADLI, role: CONTACT, phone: 05369831133, email: h.adli@hotmail.com, contacts name: Kezban BAYRAMLAR, Prof. Dr., role: SUB_INVESTIGATOR, geoPoint lat: 38.35018, lon: 38.31667, hasResults: False
protocolSection identificationModule nctId: NCT06326736, orgStudyIdInfo id: 2024NZKY-014-02, briefTitle: Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Jinling Hospital, China, class: OTHER, collaborators name: Jiangsu Synthgene Biotechnology Co.Ltd., descriptionModule briefSummary: The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines., conditionsModule conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Surgery, interventions name: Camrelizumab, interventions name: SJ-Neo006, interventions name: Gemcitabine+Abraxane, outcomesModule primaryOutcomes measure: Incidence of Treatment Emergent Adverse Events (TEAEs), secondaryOutcomes measure: Disease control rate (DCR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wang Sizhen, status: RECRUITING, city: Nanjing, state: Jiangsu, country: China, contacts name: wu qiong, role: CONTACT, phone: 02580863234, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06326723, orgStudyIdInfo id: SIM0808-101, briefTitle: Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-04, primaryCompletionDateStruct date: 2023-12-24, completionDateStruct date: 2024-02-05, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Jiangsu Simcere Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical study to assess the PK characteristics and safety and tolerability of single and multiple dose daridorexant in 32 healthy adult Chinese subjects., conditionsModule conditions: Healthy Volunteer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: Daridorexant, outcomesModule primaryOutcomes measure: Pharmacokinetic Endpoints1, primaryOutcomes measure: Pharmacokinetic Endpoints2, primaryOutcomes measure: Pharmacokinetic Endpoints3, primaryOutcomes measure: Pharmacokinetic Endpoints4, primaryOutcomes measure: Pharmacokinetic Endpoints5, primaryOutcomes measure: Pharmacokinetic Endpoints6, primaryOutcomes measure: Pharmacokinetic Endpoints7, secondaryOutcomes measure: Safety Endpoints1, secondaryOutcomes measure: Safety Endpoints2, secondaryOutcomes measure: Safety Endpoints3, secondaryOutcomes measure: Safety Endpoints4, secondaryOutcomes measure: Safety Endpoints5, secondaryOutcomes measure: Safety Endpoints6, secondaryOutcomes measure: Safety Endpoints7, secondaryOutcomes measure: Safety Endpoints8, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Nanjing Drum Tower hospital, city: Nanjing, state: Jiangsu, zip: 210000, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06326697, orgStudyIdInfo id: HIK-AZA-2023-01, briefTitle: Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Hikma Pharmaceuticals LLC, class: INDUSTRY, descriptionModule briefSummary: A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated Tablets in adult patients with AML under fasting conditions, conditionsModule conditions: Acute Myeloid Leukaemia, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Azacitidine, interventions name: Onureg, outcomesModule primaryOutcomes measure: Cmax, primaryOutcomes measure: AUC0-t, secondaryOutcomes measure: AUC0-∞, secondaryOutcomes measure: Kel, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: T1/2el, secondaryOutcomes measure: Adverse Events (AEs), secondaryOutcomes measure: Change in clinical safety labs, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06326684, orgStudyIdInfo id: 88524, briefTitle: Suvorexant and Alcohol, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-15, primaryCompletionDateStruct date: 2027-03-15, completionDateStruct date: 2027-03-15, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: University of Kentucky, class: OTHER, collaborators name: National Institute on Alcohol Abuse and Alcoholism (NIAAA), descriptionModule briefSummary: This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans., conditionsModule conditions: Alcohol Use Disorder, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Alcohol, interventions name: Placebo, interventions name: Suvorexant, interventions name: Suvorexant, outcomesModule primaryOutcomes measure: Reinforcing Effects of Alcohol, secondaryOutcomes measure: Craving, secondaryOutcomes measure: Mood, secondaryOutcomes measure: Alcohol Response, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Blood pressure, secondaryOutcomes measure: Breath Alcohol Level, secondaryOutcomes measure: Temperature, secondaryOutcomes measure: Side Effects, secondaryOutcomes measure: Delay Discounting, secondaryOutcomes measure: n-back Task, secondaryOutcomes measure: Stop-Signal Task Inhibitory Failures, secondaryOutcomes measure: Sleep, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Psychopharmacology of Addiction Laboratory, city: Lexington, state: Kentucky, zip: 40507, country: United States, contacts name: William Walton Stoops, role: CONTACT, phone: 8592575388, email: william.stoops@uky.edu, contacts name: William W Stoops, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.98869, lon: -84.47772, hasResults: False
protocolSection identificationModule nctId: NCT06326671, orgStudyIdInfo id: STXA-BE-03, briefTitle: A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: Primary Objective: To evaluate the pharmacokinetics of Tiotropium Bromide Inhalation Powder (Strength:18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co. Ltd) and reference products Tiotropium Bromide Inhalation Powder (Spiriva®, Handihaler®, Strength: 18mcg, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc) by oral inhalation of single dose in healthy participants under fasting conditions., conditionsModule conditions: Chronic Obstructive Pulmonary Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ACTUAL, armsInterventionsModule interventions name: Tiotropium Bromide Inhalation Powder, interventions name: Spiriva HandiHaler, outcomesModule primaryOutcomes measure: Peak concentration (Cmax), primaryOutcomes measure: Area under the plasma concentration versus time curve (AUC) 0-t, primaryOutcomes measure: Area under the plasma concentration versus time curve (AUC) 0-∞, secondaryOutcomes measure: The time to maximum plasma concentration (Tmax), secondaryOutcomes measure: The elimination half-life (t1/2), secondaryOutcomes measure: Terminal elimination rate constant (Kel), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Henan (Zhengzhou) Zhonghui Cardiovascular Hospital, city: Zhengzhou, state: Henan, zip: 450003, country: China, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06326658, orgStudyIdInfo id: TCM for Frequent AECOPD, briefTitle: Bufei Yishen Prescription on Patients With Frequent AECOPD in Stable Stage, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2026-10-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Henan University of Traditional Chinese Medicine, class: OTHER, collaborators name: The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, collaborators name: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, descriptionModule briefSummary: To evaluate the clinical efficacy and health economic advantages of Lung Replenishing and Kidney Enhancing Formula for the treatment of patients with frequent acute exacerbations in the stabilized phase., conditionsModule conditions: Chronic Obstructive Pulmonary Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 848, type: ESTIMATED, armsInterventionsModule interventions name: Bufei Yishen Prescription Granule, outcomesModule primaryOutcomes measure: The number of acute exacerbations, secondaryOutcomes measure: The number of AECOPD leading to hospitalization and death, secondaryOutcomes measure: Time of onset of the first AECOPD, secondaryOutcomes measure: Severity of AECOPD, secondaryOutcomes measure: Duration of AECOPD, secondaryOutcomes measure: Case fatality rate, secondaryOutcomes measure: Lung function, secondaryOutcomes measure: Score for clinical signs and symptoms, secondaryOutcomes measure: 6-minute walking distance (6MWD), secondaryOutcomes measure: The Chronic Obstructive Pulmonary Patient Self-Assessment Test (CAT), secondaryOutcomes measure: The MOS item short fromhealth survey（SF-36）, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06326645, orgStudyIdInfo id: IRB23-891, briefTitle: Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12-01, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Lindsey Russell, MD, class: OTHER, collaborators name: Napo Pharmaceuticals, Inc., descriptionModule briefSummary: The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. ., conditionsModule conditions: Short Bowel Syndrome, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Small exploratory study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: Crofelemer Oral Product, outcomesModule primaryOutcomes measure: Ostomy output reduction, secondaryOutcomes measure: Change in average weekly Parenteral Support (PS) volume, secondaryOutcomes measure: Change in SBS-QoL (Short bowel syndrome quality of life), secondaryOutcomes measure: Change in GSRS (Gastrointestinal Symptom Rating Scale), secondaryOutcomes measure: Change in intestinal absorption of fluids and macronutrients with consequent reduction of macronutrient requirements in patients with SBS, secondaryOutcomes measure: Change in weekly need for parenteral electrolytes, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cleveland Clinic Main Campus, city: Cleveland, state: Ohio, zip: 44106, country: United States, contacts name: Lindsey A Russell, MD, role: CONTACT, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False